VJHemOnc Podcast

Over the last few decades, advances in immunotherapies including CAR-T therapy have revolutionized the treatment of patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), and several clinical trials have demonstrated the efficacy of CAR-Ts in this field. Experts are also debating the possibility of bringing CAR-T therapy into earlier lines of treatment, and ongoing clinical trials are evaluating the benefits of this.

In this exclusive podcast, leading experts David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, Caron Jacobson, MD, MMSc, Dana-Farber Cancer Institute, Boston, MA, and Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discuss the current state of CAR-T therapy in lymphoma. The experts comment on moving CAR-T therapy into earlier lines of treatment, and discuss clinical trial updates, including results from the TRANSFORM study (NCT03575351) and the ZUMA-12 study (NCT03761056). This discussion took place at the 4th International Workshop on CAR-T (iwCAR-T) meeting held in Tampa, FL.

While multiple myeloma remains a challenging disease to treat, there have been several advances in the field over the years. Novel immunotherapies, including CAR-T therapy, bispecific antibodies, and antibody-drug conjugates (ADCs), continue to transform the myeloma treatment landscape and provide patients with more hope. At the 2022 EHA Annual Meeting, there were several exciting updates presented, with a large focus being placed on clinical trials and novel immunotherapies.

In this exclusive podcast, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, and Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discuss key advances in myeloma treatment from this year’s EHA meeting, drawing focus on the DETERMINATION trial (NCT01208662) and the promise of novel immunotherapies.

Classification and risk stratification are crucial for the management and treatment of patients with myelodysplastic syndromes (MDS). For many years, the gold standard for assessing disease risk has been the Revised International Prognostic Scoring System (IPSS-R). However, the recently-developed IPSS-Molecular (IPSS-M) has been evaluated and provides valuable information, improving overall risk assessment.

In this podcast, leading experts Rafael Bejar, MD, PhD, University of California San Diego, San Diego, CA, Aziz Nazha, MD, Amazon Web Services, Westlake, OH, Robert Hasserjian, MD, Massachusetts General Hospital, Boston, MA, and Jane Churpek, MD, MS, University of Wisconsin School of Medicine, Madison, WI, discuss updates in classification and risk stratification in MDS, including the value of the novel IPSS-M and the MDS Clinical Research Consortium Molecular Prognostic Tool. This discussion took place at the 1st International Workshop on Myelodysplastic Syndromes (iwMDS) held in Miami, FL.

At the Myeloma 2022 meeting held in Scottsdale, AZ, there were several fascinating sessions that took place covering a variety of topics, including novel targets, T-cell engager therapy, myeloma at the single-cell level, the role of measurable residual disease (MRD), and more. Leading experts came together to discuss, debate, and answer questions, bringing you the latest in the field.

In this exclusive podcast, Keith Stewart, MB, ChB, Princess Margaret Cancer Centre, Toronto, Canada, Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York, NY, and Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone, New York, NY, share some key highlights from day one at this year's meeting. The experts talk on updates in MRD and prognosis, antibody therapy for amyloidosis, and more. 

Myelodysplastic syndromes (MDS) are a type of rare and heterogeneous hematological malignancy, and immune dysregulation plays a major role in the development of this disease and progression to acute myeloid leukemia (AML). Several novel targets are being explored in this field with the aim of increasing treatment options for patients and improving response to therapies. 

In this exclusive podcast, you will hear from leading experts Uwe Platzbecker, MD, Leipzig University Hospital, Leipzig, Germany, Alan List, MD, Precision BioSciences, Durham, NC, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, and Daniel Starczynowski, PhD, Cincinnati Children’s Hospital, Cincinnati, OH, as they discuss immune dysregulation and targeting in MDS. This discussion took place at the 1st International Workshop on Myelodysplastic Syndromes (iwMDS) held in Miami, FL. 

Acute lymphoblastic leukemia (ALL) is an aggressive and heterogeneous disease with a high mortality rate. However, several advances have been made in recent years to improve treatment options for patients. Novel immunotherapies, such as chimeric antigen receptor T-cell (CAR-T) therapy and antibodies, are continuously being explored and have greatly changed the treatment landscape. 

In this exclusive podcast, you will hear from experts Noelle Frey, MD, MSCE, University of Pennsylvania, Philadelphia, PA, Bijal Shah, MD, Moffitt Cancer Center, Tampa, FL, and Shannon Maude, MD, PhD, Children's Hospital of Philadelphia, Philadelphia, PA, who discuss the future of CAR-T therapy in ALL, highlighting the impact of the approval of tisagenlecleucel (tisa-cel) in adult patients, the promise of allogeneic products, and more. This discussion took place at the 4th International Workshop on CAR-T (iwCAR-T) meeting held in Tampa, FL.

Multiple myeloma has seen many advances in recent years, and novel targeted agents are transforming the field. Several immunotherapies, including CAR-T therapy and T-cell engagers, are providing hope for patients, and novel targets are continuously being explored, especially in the relapsed/refractory setting.

In this exclusive podcast, leading experts Lawrence Boise, PhD, Winship Cancer Institute of Emory University, Atlanta, GA, and Paola Neri, MD, PhD, University of Calgary, Calgary, AB, Canada, discuss novel targets in multiple myeloma, including RAS and PIKfyve, and further comment on the epigenomics and epigenetics of resistance to proteasome inhibitors and IMiDs, as well as PROTAC therapy for difficult to manipulate targets.